Ongoing Assessments & Recent Research.
Easy access to our work
Smoking Cessation
Jan 2026Multiple Sclerosis: SPMS
Jun 2025Non-Cystic Fibrosis Bronchiectasis
Sep 2025Obesity Management
Nov 2025Retinitis Pigmentosa
Apr 2025Spinal Muscular Atrophy
Aug 2025Featured News & Insights.
Learn about our latest work.
Institute for Clinical and Economic Review Publishes Evidence Report on Treatment for Secondary Progressive Multiple Sclerosis
There are significant uncertainties regarding long term efficacy of tolebrutinib; ICER estimates that treatment would achieve common thresholds of cost-effectiveness if priced between $3,250 and $5,900 per year.
05/29/2025Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatments for Spinal Muscular Atrophy
Public comment period now open until June 24, 2025; Requests to make oral comment during public meeting also being accepted.
05/27/2025Institute for Clinical and Economic Review to Assess Treatment for Smoking Cessation
Report will be subject of Midwest CEPAC meeting in January 2026; Draft Scoping Document open to public comment until June 10, 2025.
05/20/2025Our Origin Story.
Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
The ICER-developed Clinical trial Diversity Rating (CDR) Tool presents a framework for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall diversity rating. Learn more.
Current
Policy Papers.
Easy access to our latest policy papers
Examining Strategies to Ensure Affordable Access for Obesity Medications
ICER, in collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications.
The paper seeks to present insights and lessons learned from experts, while offering a menu of options that will help all stakeholders play an active part in an innovative future of pricing, coverage, and payment for new obesity medications.
Special Report on COPD Therapies as Part of CMS Public Comment Process on Medicare Drug Price Negotiations
ICER developed a special report for CMS on two therapies in high demand for treating chronic obstructive pulmonary disease (COPD). This report was submitted to CMS as part of the 2025 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2027.